Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tifalibep
- Development stage
- Discontinued
- Lead developer
- Affibody
- Modality
- Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
ABY-039, also known as tifalibep, is a bivalent antibody-mimetic designed to target the neonatal Fc receptor (FcRn). It acts as an FcRn antagonist, disrupting the interaction between FcRn and immunoglobulin G (IgG), which accelerates the clearance of pathogenic IgG autoantibodies from circulation. This mechanism is intended to treat IgG-mediated autoimmune diseases by lowering plasma IgG titers. ABY-039 was developed using Affibody’s proprietary technology platform and is notable for its small size (18 kDa), long half-life, and potential for subcutaneous administration. The drug underwent Phase 1 clinical trials in healthy volunteers but development has since been terminated[1][2][4][5][6].
- Other names
- tifalibep
02
Targets
FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on tifalibep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tifalibep.